



NATH SEEDS®

Nath Bio-Genes (I) Ltd.

(CIN L01110MH1993PLC072842)

30th May, 2019.

The Manager-Listing
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400001

The Manager- Listing
National Stock Exchange of India Ltd.,
Exchange Plaza, Bandra-Kurla Complex
Bandra (E)
Mumbai-400051

BSE Code-537291

NSE Code-NATHBIOGEN

Dear Sirs,

Sub - Outcome of Board Meeting.

Ref - Regulation 30 and Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements)

We inform you that the Board of Directors of the Company, at its Meeting held today i.e. on 30th May 2019, Commenced on 02:00 p.m. and Concluded at 04:30 p.m. have considered and approved, inter alia, the following items of Business;

1. Audited Financial Results for the quarter and financial year ended i.e. 31st March 2019, a copy of the same is enclosed along with Auditors Report issue on Financial Results.
2. Declaration Pursuant to Regulation 33(3) (d) of the Listing Regulation, regarding unmodified opinion of the Statutory Auditors on the Financial Results.
3. The Annual General Meeting of the Company is scheduled to be on Saturday 10th August 2019.
4. Register of Members' and share transfer books will remain close from 05th August 2019 to 10th August 2019, for Annual General Meeting.
5. Appointment of Mrs. Jeevanlata Nandkishor Kagliwal (DIN-02057459) as additional director of the Company up-to the upcoming annual general meeting of the Company. (brief profile of Mrs. Jeevanlata Nandkishor Kagliwal is annexed for reference)



NATH SEEDS®

Nath Bio-Genes (I) Ltd.

(CIN L01110MH1993PLC072842)

6. Re-appointment of Mr. Kashinath Ganapathy Iyer (DIN-01195975) as Independent Director of the Company for the period of 5 years subject to approval of Shareholder in ensuring annual general meeting.

We request you take the same on record.

Thanking You

For Nath Bio-Genes (India) Limited

Devinder Khurana
Chief Financial Officer

NATH SEEDS

हर बीज खरा, शक्ति भरा



Nath Bio-Genes (I) Ltd.

(CIN L01110MH1993PLC072842)

STATEMENT OF STANDALONE AUDITED RESULTS FOR THE QUARTER AND YEAR ENDED 31/03/2019

		Rs in Lacs				
S. No.	Particulars	Quarter Ended			Year Ended	
		31/03/2019 Audited	31/12/2018 Unaudited	31/03/2018 Audited	31/03/2019 Audited	31/03/2018 Audited
I	Income					
	(a) Revenue from operations	5230.91	2787.71	5001.19	23092.89	19165.08
	(b) Other Operating Income	42.23	38.77	81.44	227.35	94.41
	Total Income	5273.14	2826.48	5082.63	23320.24	19259.49
II	Expenses					
	a) Cost of Material Consumed	4715.11	2430.91	3170.65	13061.85	7488.67
	b) Purchase of Stock-in-Trade	283.06	75.69	108.40	549.18	271.19
	c) Changes in Inventory of Finished Goods & Work in Progress	(2158.31)	(1692.44)	(1070.04)	(3046.07)	679.45
	d) Employee Benefit Expense	441.01	464.25	391.55	1642.81	1365.64
	e) Finance Costs	134.76	173.86	205.41	520.46	1030.95
	f) Depreciation & Amortisation Expenses	39.66	35.00	20.07	144.66	95.07
	g) Selling & Distribution Expenses	775.59	449.16	1177.66	4418.40	3433.08
	h) Other Expenditure	594.65	462.94	859.99	2142.14	1889.99
	Total Expenses	4825.53	2399.36	4863.68	19433.42	16254.04
III	Profit before Exceptional Items & Tax (I - II)	447.61	427.12	218.94	3886.82	3005.45
IV	Exceptional Items Income/(Expenses)	0.00	0.00	13.86	0.00	0.00
V	Profit Before Tax (III+IV)	447.61	427.12	205.08	3886.82	3005.45
VI	Tax Expense					
	(a) Current Tax	(116.42)	77.40	31.72	10.98	64.39
	(b) Earlier Year Tax				18.71	
	(b) Deferred Tax	13.79	0.00	(0.79)	13.79	(0.79)
VII	Net Profit for the period (V-VI)	550.24	349.72	174.15	3843.34	2941.85
VIII	Other Comprehensive Income					
	1. (a) Items that will not be reclassified to Profit or Loss	8.39	0.00	0.00	8.39	0.00
	(b) Income tax relating to items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00
	2. (a) Items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00
	(b) Income tax relating to items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00
	Total other Comprehensive Income	8.39	0.00	0.00	8.39	0.00
IX	Total Comprehensive Income for the period (VII + VIII)	541.85	349.72	174.15	3834.95	2941.85
X	Paid Up Equity Share Capital (Face Value Rs. 10/- each)	1900.40	1900.40	1900.40	1900.40	1900.40
XI	Reserves (excluding Revaluation Reserves) as per balance sheet of previous year	48857.67	48334.52	45022.72	48857.67	45022.72
XII	Earning per share (of Rs 10/- each) (not annualised) Basic & Diluted	2.90	1.84	0.92	20.22	15.48

NOTES:

- The financial results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at its meeting held on 30th May 2019. The statutory auditors of the Company have carried out audit of the financial results.
- The company is dealing in one major product segment, i.e. Seed Cultivation.
- The figures for the Quarter ending 31.03.2019 are the balancing figures between the audited figures of the full financial year and the year to date figures up to the third quarter.
- The figures have been regrouped/rearranged where ever necessary.

FOR NATH BIO-GENES (INDIA) LTD

Place : Aurangabad

Date : 30th May 2019

[Signature]
Satish Kagiwal
MANAGING DIRECTOR
DIN 00119601

Regd. Office : Nath House, Nath Road, Aurangabad - 431005 (MS)
www.nathbiogenes.com

ASHOK R. MAJETHIA & CO.

Chartered Accountants

[Signature]
ASHOK R. MAJETHIA
PROPRIETOR

MEMBERSHIP NO. 124781

Nath Bio-Genes (India) Limited
Standalone Statement of Assets and Liabilities

		Rs. In Lacs	
	Particulars	As at Year end 31.03.2019	As at Year end 31.03.2018
		(Audited)	(Audited)
A	ASSETS		
	(1) Non Current Assets		
	a) Property, Plant & Equipment	22811.51	20694.23
	b) Capital Work in Progress	0.00	0.00
	c) Other Intangible Assets	360.00	400.00
	d) Intangible Assets under Development	0.00	0.00
	e) Financial Assets		
	(i) Investments	499.73	499.70
	(ii) Others	18.17	18.15
	f) Deferred Tax Assets (Net)	72.40	86.20
	g) Other Non Current Assets	126.57	1.55
	Total Non Current Assets	23888.38	21699.83
	(2) Current Assets		
	a) Inventories	15535.62	12345.72
	b) Financial Assets		
	(i) Investments	0.00	0.00
	(ii) Trade Receivables	10802.50	8204.93
	(iii) Cash and Cash Equivalents	2137.93	4465.83
	(iv) Bank balance other than (iii) above	0.00	0.00
	(v) Loans	11868.90	9823.06
	c) Current Tax Assets	216.44	430.38
	d) Other Current Assets	156.56	150.74
	Total Current Assets	40717.95	35420.66
	TOTAL ASSETS	64606.33	57120.49
B	EQUITIES AND LIABILITIES		
	1. Shareholders' Fund		
	(a) Share capital	1900.40	1900.40
	(b) Other Equity	48857.66	45022.72
	Total Equity	50758.06	46923.12
	Liabilities		
	4. Non-current liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	50.46	31.01
	(b) Provisions	188.77	187.82
	c) Other non-current liabilities	0.00	0.00
	Total Non-current liabilities	239.23	218.83
	Current Liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	5719.06	3204.04
	(ii) Trade Payables	5020.13	3659.93
	b) Other Current Liabilities	2780.33	2783.61
	c) Provisions	37.07	35.99
	Current Tax Liabilities	52.45	294.96
		13609.04	9978.53
	TOTAL - EQUITY AND LIABILITIES	64606.33	57120.48

ASHOK R. MAJETHIA & CO.
Chartered Accountants

ASHOK R. MAJETHIA
PROPRIETOR
MEMBERSHIP NO. 124781

FOR NATH BIO-GENES (INDIA) LTD

Satish Kagliwal
MANAGING DIRECTOR
DIN00119601

Place : Aurangabad
Date : 30 May 2019

ASHOK R. MAJETHIA

B.Com. F.C.A

CHARTERED ACCOUNTANT

Ashok R. Majethia & Co.

Chartered Accountants

Utsav Complex,

Office No. 7, Bazar Peth,

Dist. Raigad, Khopoli – 410 203

Tel :- (02192) 269908

Mobile :- 9404711539 / 9372169952

Email :- ashokmajethia@rediffmail.com

INDEPENDENT AUDITORS' REPORT ON QUARTER AND ANNUAL FINANCIAL RESULTS PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

To

The Board of Directors of
Nath Bio-genes (I) Limited

1. We have audited the accompanying statement of financial results for the quarter ended 31st March 2019 (the Statement) of Nath Bio-genes (I) Limited (the Company). This statement has been prepared by the Company pursuant to regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 (the "Listing Regulation, 2015" read with SEBI circular dated July 05, 2016 which has been initialed by us for identification purposes.
2. The preparation of the statement in accordance with the the recognition and measurement principle laid down in the Indian Accounting Standard 34 – "Interim Financial Reporting" as prescribed under section 133 of the Companies Act, 2013 read with the rule no 3 of the Companies (Accounting Standard Rule) 2015, as amended read with the circular, is the responsibility of the Company's management and has been approved by the Board of Directors of the Company in the meeting held on 30th May 2019. Our responsibility is to express a conclusion on statements based on our audit.
3. We conducted our audit in accordance with the Standard on Auditing issued by Institute of Chartered Accountants of India. Those Standard require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statement is free from material mis-statement



4. An audit involves performing procedures to obtain audit evidence about the amount and the disclosure in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risk of material misstatement of the statement, whether due to fraud or error. In making those risk assessments, the auditors consider internal control relevant to the company's preparation and fair presentation of the statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of the accounting principles used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Financial Statement.
5. We believe that the audit evidence, we have obtained is sufficient and appropriate to provide a basis for our audit opinion,
6. In our opinion and to the best of information and according to explanation given to us, the Statement
- a. is presented in accordance with the requirements of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirement) Regulation 2015 as modified by Circular No CIR/CFD/FAC/62/2016 dated 05th July 2016; and
 - b. give a true and fair view in conformity with the aforesaid Accounting Standard and other accounting principles generally accepted in India of the Profit and other financial information of the Company for the quarter and year ended on 31st March 2019.
7. This statement includes the results for the quarter ended on 31st March 2019 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures upto the third quarter of the current financial year which were subject to Limited Review by us.

For Ashok R Majethia
Chartered Accountants
FRN: 127769W



Ashok Majethia
Proprietor
M No: 124781



Place: Aurangabad
Date: 30.05.2019



NATH SEEDS®

Nath Bio-Genes (I) Ltd.

(CIN L01110MH1993PLC072842)

30th May 2019

The Manager-Listing
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400001

The Manager- Listing
National Stock Exchange of India Ltd.,
Exchange Plaza, Bandra-Kurla Complex
Bandra (E)
Mumbai-400051

BSE Code-537291

NSE Code-NATHBIOGEN

Dear Sirs,

Sub: Declaration with respect to Audit Report with unmodified opinion to the Audited Financial Results (Standalone) for the quarter and Financial year ended March 31, 2019.

In compliance with Regulation 33(3) (d) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended, we confirm that the Statutory Auditors of the Company, M/s Ashok R Majethia & Co., (Firm Regn No-127769) Chartered Accountants, have not expressed any modified opinion in their Audit Report Pertaining to the Audited Financial Results of Nath Bio-Genes (India) Limited for the quarter and financial year ended 31st March 2019.

We request you take the same on record.

Thanking You

For Nath Bio-Genes (India) Limited

Devinder Khurana
Chief Financial Officer



NATH SEEDS®

Nath Bio-Genes (I) Ltd.

(CIN L01110MH1993PLC072842)

Annexure-

Brief Profile of Mrs. Jeevanlata Nandkishor Kagliwal, Additional Director.

Date of Birth	30 th April 1948
Nationality	Indian
Date of Appointment	30 th May 2019
Qualification	M.A. Political Science
Expertise in specific functional area	She is having Immense experience in the field of Management
Directorship in other Companies	<ol style="list-style-type: none">1. Rama Pulp and Papers Limited2. Nath Pulp and Papers Mills Limited3. Global Transgenes Limited4. Nath Industrial Chemical Limited5. Nath Royal Seeds Limited6. Prabha Farms Private Limited7. Paresh Farms Private Limited8. Jeevan Farms Private Limited9. Nath Bio-Technologies Limited10. Ferry Fax Farms Private Limited
Membership In Committees	Not Applicable
Numbers of Shares Held	293 Shares



NATH SEEDS
हर वा न खरा, शक्ति भरा

■ Nath House, Nath Road, Aurangabad - 431005 (MS) Tel : 0240-2376314/5/6/7
Email : info@nathseeds.com www.nathbiogenes.com

■ 1, Chateau Windsor, 86 Veer Nariman Road, Mumbai - 400020 (MS) Tel : 022-22871001, 22875653/4/5

NATH
GROUP